The validity of health-related quality of life questionnaires in bronchiectasis: A systematic review and meta-analysis

Thorax

Volumn 71, Issue 8, 2016, Pages 683-694

  Spinou, Arietta ^a   Fragkos, Konstantinos C ^b   Lee, Kai K ^c   Elston, Caroline ^c   Siegert, Richard J ^d   Loebinger, Michael R ^e   Wilson, Robert ^e   Garrod, Rachel ^a   Birring, Surinder S ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

^d AUCKLAND UNIVERSITY OF TECHNOLOGY   (New Zealand)

^e ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANALYTICAL PARAMETERS; ARTICLE; BRONCHIECTASIS; COMPUTER ASSISTED TOMOGRAPHY; CONVERGENT VALIDITY; CORRELATIONAL STUDY; CROSS CULTURAL TRANSLATION VALIDITY; DATA BASE; DISCRIMINANT VALIDITY; DYSPNEA; EXERCISE; FATIGUE; FLOOR AND CEILING EFFECT; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; INTERNAL CONSISTENCY; LEICESTER COUGH QUESTIONNAIRE; MISSING DATA; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PSYCHOMETRY; QUALITY OF LIFE ASSESSMENT; QUALITY OF LIFE BRONCHIECTASIS QUESTIONNAIRE; RESPIRATORY TRACT DISEASE ASSESSMENT; RESPONSIVENESS; SHORT FORM 36; ST. GEORGE RESPIRATORY QUESTIONNAIRE; SYSTEMATIC REVIEW; TEST RETEST RELIABILITY; VALIDATION STUDY; VALIDITY; COMPLICATION; COUGH; HEALTH STATUS; META ANALYSIS; PSYCHOLOGY; QUALITY OF LIFE; QUESTIONNAIRE; REPRODUCIBILITY;

BRONCHIECTASIS; COUGH; DYSPNEA; HEALTH STATUS; HUMANS; PSYCHOMETRICS; QUALITY OF LIFE; REPRODUCIBILITY OF RESULTS; SURVEYS AND QUESTIONNAIRES;

EID: 84959092717     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2015-207315     Document Type: Article

References (39)

1. Swigris JJ, Kuschner WG, Jacobs SS, et al. Health-related quality of life in patients with idiopathic pulmonary fibrosis: a systematic review. Thorax 2005;60:588-94.
2. Pasteur MC, Bilton D and Hill AT. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010;65(Suppl 1):i1-58.
3. Martínez-Garcia MA, Perpiñá-Tordera M, Román-Sánchez P, et al. Quality-of-life determinants in patients with clinically stable bronchiectasis. Chest 2005a;128: 739-45.
4. Jacques PS, Gazzana MB, Palombini DV, et al. Six-minute walk distance is not related to quality of life in patients with non-cystic fibrosis bronchiectasis. J Bras Pneumol 2012;38:346-55.
5. Wilson CB, Jones PW, O'Leary CJ, et al. Validation of the St. George's Respiratory Questionnaire in bronchiectasis. Am J Respir Crit Care Med 1997;156(2 Pt 1):536-41.
6. Quittner AL, Marciel KK, Salathe MA, et al. A preliminary quality of life questionnaire-bronchiectasis: a patient-reported outcome measure for bronchiectasis. Chest 2014;146:437-48.
7. Murray MP, Turnbull K, MacQuarrie S, et al. Validation of the Leicester Cough Questionnaire in non-cystic fibrosis bronchiectasis. Eur Respir J 2009a;34:125-31.
8. Group PRISMA. The PRISMA statement. http://www.prisma-statement.org/(accessed 8 Apr 2014).
9. Scottish Intercollegiate Guidelines Network. SIGN methodology checklist 1: systematic reviews and meta-Analyses. http://www.sign.ac.uk/methodology/checklists.html (accessed 8 Apr 2014).
10. Rosenthal R, Rosnow R, Land Rubin DB. Contrasts and effect sizes in behavioral research: a correlational approach. Cambridge: Cambridge University Press, 2000.
11. Higgins J, Deeks J. Selecting studies and collecting data. In: Higgins J, Green S, eds. Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. http://handbook.cochrane.org/(accessed 8 Apr 2014).
12. Fragkos KC, Tsagris M, Frangos CC. Publication bias in meta-Analysis: confidence intervals for Rosenthal's fail-safe number. Int Scholarly Res Notices 2014;2014 (Article ID 825383):1-17.
13. Quittner AL, Cruz I, Marciel KK, et al. Development and cognitive testing of the Quality of Life Questionnaire for Bronchiectasis (QOL-B). Am J Respir Crit Care Med 2010;179:A4310 (Abstract).
14. Munoz G, Olveira C, Martinez-Garcia MA, et al. Validation of a Spanish version of the Leicester Cough Questionnaire in adult patients with non-cystic fibrosis bronchiectasis. Eur Respir J 2013;42(Suppl 57):P5068 (Abstract).
15. Tomkinson JL, Bruton A. The 6-minute walk test for patients with bronchiectasis: comparison with normal predictive data. Journal of the Association of Chartered Physiotherapists in Respiratory Care 2009;41:16-21.
16. Loebinger MR, Wells AU, Hansell DM, et al. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J 2009;34:843-9.
17. Chan SL, Chan-Yeung MM, Ooi GC, et al. Validation of the Hong Kong Chinese version of the St. George Respiratory Questionnaire in patients with bronchiectasis. Chest 2002;122:2030-7.
18. Girón Moreno RM, Fernandes Vasconcelos G, Cisneros C, et al. Presence of anxiety and depression in patients with bronchiectasis unrelated to cystic fibrosis. Arch Bronconeumol 2013;49:415-20 (Abstract).
19. Murray MP, Twiss J, McKenna SP, et al. The utility of the nottingham health profile in exacerbations of non-cystic fibrosis bronchiectasis. Thorax 2010;65:A176 (Abstract).
20. Quittner AL, Salathe M, Gotfried M, et al. National validation of a patient-reported outcome measure for bronchiectasis: psychometric results on the QOL-B. Am J Respir Crit Care Med 2010;181:A5793 (Abstract).
21. Olveira C, Olveira G, Espildora F, et al. Validation of a quality of life questionnaire for bronchiectasis: psychometric analyses of the Spanish QOL-B-V3.0. Qual Life Res 2014;23:1279-92.
22. Murray MP, Turnbull K, Macquarrie S, et al. Assessing response to treatment of exacerbations of bronchiectasis in adults. Eur Respir J 2009;33:312-18.
23. Courtney JM, Kelly MG, Watt A, et al. Quality of life and inflammation in exacerbations of bronchiectasis. Chron Respir Dis 2008;5:161-8.
24. Altenburg J, Wortel K, de Graaff CS, et al. Validation of a visual analogue score (LRTI-VAS) in non-CF bronchiectasis. Clin Respir J 2016;10:168-75.
25. Lee AL, Cecins N, Hill CJ, et al. Utility of the chronic respiratory questionnaire in non-cystic fibrosis (CF) bronchiectasis. Respirology 2010;15:A78 (Abstract).
26. Morsi TS, Ghobashy S, Younis G. Quality of life and psychological disorders in Egyptian patients with chronic lung diseases: clinico-physiological correlation. Egypt J Chest Dis Tuberc 2014;63:731-42.
27. Ozalp O, Inal-Ince D, Calik E, et al. Extrapulmonary features of bronchiectasis: muscle function, exercise capacity, fatigue, and health status. Multidiscip Respir Med 2012;7:3.
28. Polley L, Yaman N, Heaney L, et al. Impact of cough across different chronic respiratory diseases: comparison of two cough-specific health-related quality of life questionnaires. Chest 2008;134:295-302.
29. Torrego A, Haque RA, Nguyen LT, et al. Capsaicin cough sensitivity in bronchiectasis. Thorax 2006;61:706-9.
30. Martinez Garcia MA, Perpina Tordera M, Roman Sanchez P, et al. Internal consistency and validity of the Spanish version of the St. George's respiratory questionnaire for use in patients with clinically stable bronchiectasis. Arch Bronconeumol 2005b;41:110-17.
31. Guilemany JM, Alobid I, Angrill J, et al. The impact of bronchiectasis associated to sinonasal disease on quality of life. Respir Med 2006;100:1997-2003.
32. Lee BY, Lee S, Lee JS, et al. Validity and reliability of CAT and Dyspnea-12 in Bronchiectasis and Tuberculous destroyed lung. Tuberc Respir Dis (Seoul) 2012;72:467-74.
33. Quittner AL, O'Donnell AE, Salathe MA, et al. Quality of life questionnaire-bronchiectasis: final psychometric analyses and determination of minimal important difference scores. Thorax 2015;70:12-20.
34. Wilson CB, Jones PW, O'Leary CJ, et al. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur Respir J 1997b;10:1754-60.
35. Chalmers JD, Goeminne P, Aliberti S, et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care Med 2014;189:576-85.
36. Food and Drug Association (FDA). Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. In: Services USDoHaH, Administration FaD, (CDER) CfDEaR, et al., eds. 2009:1-39. http://www.fda.gov/downloads/Drugs/.../Guidances/UCM193282.pdf (accessed 8 Apr 2014).
37. Barker AF, O'Donnell AE, Flume P, et al. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials. Lancet Respir Med 2014;2:738-49.
38. Wild D, Grove A, Martin M, et al. Principles of good practice for the translation and cultural adaptation process for Patient-Reported Outcomes (PRO) measures: report of the ISPOR task force for translation and cultural adaptation. Value Health 2005; 8:94-104. .
39. Ketelaars CA, Schlösser MA, Mostert R, et al. Determinants of health-related quality of life in patients with chronic obstructive pulmonary disease. Thorax 1996;51:39-43.